

TAVI for low-flow, low-gradient severe aortic stenosis with preserved or reduced ejection fraction: a subgroup analysis from the German Aortic Valve Registry (GARY)

Alexander Lauten^{1*}, MD; Hans R. Figulla², MD; Helge Möllmann², MD; David Holzhey³, MD; Joachim Kötting⁴, MSc; Andreas Beckmann⁵, MD; Christof Veit⁴, MD; Jochen Cremer⁶, MD; Karl-Heinz Kuck⁷, MD; Rüdiger Lange⁸, MD; Ralf Zahn⁹, MD; Stefan Sack¹⁰, MD; Gerhard Schuler³, MD; Thomas Walther¹¹, MD; Friedhelm Beyersdorf¹², MD; Michael Böhm¹³, MD; Gerd Heusch¹⁴, MD; Thomas Meinertz¹⁵, MD; Till Neumann¹⁶, MD; Armin Welz¹⁷, MD; Friedrich W. Mohr³, MD; Christian W. Hamm², MD; on behalf of the GARY Executive Board

1. Department of Internal Medicine I, University Heart Center Jena, Jena, Germany; 2. Department of Cardiology, Kerckhoff-Klinik, Bad Nauheim, Germany; 3. Leipzig Heart Center, University of Leipzig, Leipzig, Germany; 4. BQS Institute for Quality and Patient Safety, Düsseldorf, Germany; 5. Department of Cardiac and Vascular Surgery, Heart Center Duisburg, Duisburg, Germany; 6. Department of Cardiovascular Surgery, University Hospital Schleswig-Holstein, Kiel, Germany; 7. Department of Cardiology, Asklepios Klinik St. Georg, Hamburg, Germany; 8. Department of Cardiovascular Surgery, German Heart Center, Munich, Germany; 9. Department of Cardiology, Heart Center Ludwigshafen, Ludwigshafen, Germany; 10. Department of Cardiology, Klinikum Muenchen Schwabing, Munich, Germany; 11. Department of Cardiac Surgery, Kerckhoff-Klinik, Bad Nauheim, Germany; 12. Department of Cardiac Surgery, Heart Center Freiburg University, Freiburg, Germany; 13. Klinik für Innere Medizin III, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany; 14. Institut für Pathophysiologie, Universitätsklinikum Essen, Essen, Germany; 15. Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany; 16. Department of Cardiology, West German Heart Center Essen, Essen, Germany; 17. Department of Cardiac Surgery, University Hospital Bonn, Bonn, Germany

KEYWORDS

- paradoxical low-gradient aortic stenosis
- transcatheter aortic valve replacement

Abstract

Aims: The study analyses the outcome of patients undergoing transcatheter aortic valve implantation (TAVI) for different subtypes of severe aortic stenosis (AS) based on data from the GARY registry.

Methods and results: Low-EF, low-gradient (LEF-LGAS: EF \leq 40%, MPG <40 mmHg), paradoxical low-gradient (PLF-LGAS: EF \geq 50%, MPG <40 mmHg) and high-gradient AS (HGAS: MPG \geq 40 mmHg) were observed in 11.7% (n=359), 20.8% (n=640) and 60.6% (n=1,864) of the study population, respectively. EuroSCORE I (36.7 \pm 20.9 vs. 22.6 \pm 15.7 vs. 24.3 \pm 17.4; p<0.001) differed significantly among subgroups. In-hospital and one-year mortality were higher in patients with LEF-LGAS compared to HGAS (in-hospital: 7.8% vs. 4.9%; p=0.029; one-year: 32.3% vs. 19.8%; p=0.001). In contrast, mortality in patients with PLF-LGAS was comparable to patients with HGAS (in-hospital: PLF-LGAS: 5.3%; p=0.67; one-year: 22.3%; p=0.192). The rate of TAVI-associated complications was not significantly different among groups. However, postoperative low cardiac output occurred significantly more frequently in patients with LEF-LGAS.

Conclusions: Severe AS with a reduced transaortic flow and gradient is a common finding and is present in >30% of patients undergoing TAVI. Patients with low flow and impaired LV function have a significantly higher mortality within the first year after TAVI. In contrast, the outcome of patients with low flow and preserved EF is comparable to those with a high transvalvular aortic gradient.

*Corresponding author: Department of Internal Medicine I, University Heart Center Jena, Erlanger Allee 101, 07747 Jena, Germany. E-mail: alexander.lauten@med.uni-jena.de

Introduction

Based on the current European and American guidelines, severe aortic stenosis (AS) is defined as an effective aortic valve area (AVA) of $<1 \text{ cm}^2$ (or indexed for body surface area [BSA], $\text{AVA/BSA} <0.6 \text{ cm}^2/\text{m}^2$) and a mean pressure gradient (MPG) and peak velocity (v_{max}) of $>40 \text{ mmHg}$ and 4.0 m/s , respectively^{1,2}. Transcatheter aortic valve implantation (TAVI) is the treatment of choice for patients with symptomatic severe AS and a high or prohibitive surgical risk³⁻⁶.

However, in clinical practice there is frequently an inconsistency in diagnostic criteria in patients in whom AS appears to be severe based on AVA ($<1 \text{ cm}^2$ or $<0.6 \text{ cm}^2/\text{m}^2$) but moderate or even mild based on transvalvular gradients⁷⁻¹¹. This inconsistency is caused by a reduced left ventricular (LV) stroke volume, which leads to a reduction of transaortic flow and gradient. This occurs in patients with severe AS and an ejection fraction (EF) $\leq 40\%$ (low-EF, low-gradient AS: LEF-LGAS), a subgroup which has a particularly poor prognosis with medical treatment and an increased mortality when undergoing surgical aortic valve replacement or TAVI¹²⁻¹⁴.

Editorial, see page 775

Recently, a second type of low-gradient AS has been reported with low-flow conditions caused by a decreased stroke volume due to a small LV cavity size and a restrictive physiology¹¹. This phenomenon has been described as “paradoxical” low-flow, low-gradient AS (PLF-LGAS), as it is observed in patients with severe AS despite an EF $\geq 50\%$ ^{8,15-17}. The optimal treatment and prognostic impact of PLF-LGAS on early and long-term survival after TAVI are still matters of debate. Therefore, the purpose of this study was to compare the outcome of TAVI in these distinct subgroups of AS based on data from the German Aortic Valve Registry (GARY)¹⁸⁻²⁰.

Methods

REGISTRY DESIGN AND SUBGROUPS

GARY is a prospective, multicentre registry designed to monitor the efficacy and outcome of interventional and surgical aortic valve procedures in Germany. The registry design has been described previously^{20,21}. In brief, data at 78 tertiary cardiovascular centres were collected using standardised case report forms to record demographic and clinical characteristics as well as procedural and follow-up data. The present analysis focuses on data acquired in 2011. Follow-up was obtained at 30 days and at one year based on the medical records and on physician and patient interviews. The investigators had full access to the data and control of the analysis. Ethics approval was obtained from all participating centres, and patients' written, informed consent was obtained preoperatively.

All patients undergoing aortic valve procedures were eligible for inclusion. Out of 13,860 consecutive patients enrolled in 2011, 3,908 underwent catheter-based aortic valve implantation. At the participating institutions, the decision to perform TAVI was made by a Heart Team in 87.4% of the cases based upon the established criteria^{2,22}. For the present analysis, patients were assigned to one of three subgroups depending on left ventricular ejection fraction (LVEF), mean transvalvular aortic gradient (MPG), and aortic valve area indexed for body surface area (AVA/BSA):

- (I) Group LEF-LGAS: EF $\leq 40\%$, MPG $<40 \text{ mmHg}$, AVA/BSA $\leq 0.6 \text{ cm}^2/\text{m}^2$ (low-flow, low-gradient AS).
- (II) Group PLF-LGAS: EF $\geq 50\%$, MPG $<40 \text{ mmHg}$, AVA/BSA $\leq 0.6 \text{ cm}^2/\text{m}^2$ (“paradoxical” low-flow, low-gradient AS).
- (III) Group HGAS: MPG $\geq 40 \text{ mmHg}$, AVA/BSA $\leq 0.6 \text{ cm}^2/\text{m}^2$ (high-gradient AS).

DEVICES

Patients undergoing TAVI with all commercially available devices were eligible for inclusion. During the period of enrolment, the following devices were commercially available in Germany: the balloon-expandable Edwards SAPIEN XT, a cobalt-chromium stent (sizes 23 mm, 26 mm, and 29 mm) (Edwards Lifesciences, Irvine, CA, USA), and the Medtronic CoreValve™ (sizes 26 mm, 29 mm, and 31 mm) (Medtronic, Minneapolis, MN, USA), a porcine pericardial tissue valve in a self-expanding nitinol stent frame. For implantation of the balloon-expandable device, the Ascendra delivery system (Edwards Lifesciences) was used for transapical access and the RetroFlex delivery system or, more recently, the NovaFlex delivery system (both Edwards Lifesciences) were used for transfemoral access.

The JenaValve™ (sizes 23 mm, 25 mm, and 27 mm) (JenaValve Technology GmbH, Munich, Germany), a natural porcine aortic root mounted on a nitinol stent, and the Symetis ACURATE™ valve (sizes small, medium, and large) (Symetis SA, Ecublens, Switzerland), a porcine pericardial valve mounted on a nitinol frame, were available as transapical devices.

ENDPOINTS

Major clinical endpoints were defined and analysed as reported previously²¹. The primary endpoint of the present analysis was all-cause mortality at hospital discharge and at one year. Mortality at both time points was further subdivided into cardiovascular and non-cardiovascular mortality as reported in the VARC definitions²². Further endpoints evaluated procedural characteristics (procedural success, device type and access route, device function) as well as the rate of adverse events (postoperative low cardiac output [defined as a CI $<2.2 \text{ l/min/m}^2$], myocardial infarction, stroke, acute kidney injury, bleeding and vascular complications, requirement for permanent pacemaker)^{21,22}. After device implantation, the degree of aortic regurgitation was classified on a graded scale from 0 to 4, with a higher grade indicating greater severity (grade 0=none; grade I=trace, grade II=mild; grade III=moderate, grade IV=severe).

CALCULATION OF RISK SCORES

The baseline operative risk for cardiovascular surgery was estimated using the logistic European System for Cardiac Operative Risk Evaluation (EuroSCORE system), which is calculated by a logistic regression equation (on a scale from 0 to 100%, with higher scores indicating greater risk and a score of more than 20% indicating very high surgical risk). In addition, the German Aortic Valve (German AV) Score, which is based on aortic valve procedures, was calculated by a logistic regression, with higher scores indicating greater risk²³.

The German AV score is calculated from 15 variables (further details: <http://www.bqs-outcome.de/2008/ergebnisse/leistungsbereiche/htc>).

STATISTICS

Categorical variables are presented as percentages and values, and continuous data are expressed as mean±standard deviation (SD). The comparison of baseline values among the subgroups was performed by the Kruskal-Wallis test (any differences) or Mann-Whitney U test (pairwise) for continuous variables. Categorical variables were compared by means of the χ^2 test and the Fisher's exact test where applicable. Statistical significance was tested two-sided with the alpha level of 5%. Pairwise results were corrected with the Bonferroni-Holm-Shaffer procedure for multiple comparison.

The vital status of patients already discharged or transferred to a rehabilitation programme was verified by follow-up calls. Survival curves were constructed for time-to-event variables using Kaplan-Meier estimates and compared by the log-rank test.

Backward and forward stepwise logistic regression analysis was performed to identify independent predictors of in-hospital mortality in the overall TAVI population and separately in the three groups.

A covariate (LEF-LGAS, PLF-LGAS, HGAS, age >80 years, frailty, diabetes, COPD, CAD-3, pulmonary hypertension, peripheral vascular disease, previous cardiac operations, myocardial infarction, and LVEF $\leq 30\%$) was removed from the model if the p-value exceeded 0.10. All p-values <0.05 were considered statistically significant. All statistical analyses were performed using the SPSS statistical package version 19.0.0 (IBM Corp., Armonk, NY, USA). Data management and statistical analyses were performed by the BQS Institute for Quality and Patient Safety, Dusseldorf, Germany.

Results

PATIENT POPULATION

The present study focuses on 3,908 TAVI patients included in the registry between January 1 and December 31, 2011. Complete datasets were available for 3,077 patients which were analysed in this study. Patient demographics and baseline characteristics are detailed in **Table 1**. In the study population, PLF-LGAS and LEF-LGAS were present in 640 (20.8%) and 359 (11.7%) patients, respectively (**Figure 1**); 1,864 (60.6%) patients presented with HGAS. Patients with PLF-LGAS were slightly younger than patients with HGAS

Table 1. Baseline characteristics.

	LEF-LGAS (n=359)	<i>p</i> [#] LEF-LGAS vs. PLF-LGAS	PLF-LGAS (n=640)	<i>p</i> [#] PLF-LGAS vs. HGAS	HGAS (n=1,864)	<i>p</i> [†]
Age, years±SD	79.1±6.1	0.001	80.5±5.6	<0.001	81.4±6.1	<0.001
Female, n (%)	121 (33.7)	<0.001	370 (57.8)	0.207	1,132 (60.7)	<0.001
Body mass index (kg/m ²)	26.5±4.4	<0.001	27.7±4.9	0.001	27.0±4.9	<0.001
Logistic EuroSCORE (%)	36.7±20.9	<0.001	22.6±15.7	0.071	24.3±17.4	<0.001
German AV score (%)	11.0±10.7	<0.001	7.4±7.5	0.031	8.2±8.9	<0.001
Previous medical history						
Chronic obstructive pulmonary disease, n (%)	79 (22.0)		138 (21.6)		362 (19.4)	0.328
Peripheral vascular disease, n (%)	105 (29.2)	0.005	136 (21.3)	0.116	343 (18.4)	<0.001
Pulmonary hypertension, n (%)	163 (45.4)	0.009	235 (36.7)	0.599	662 (35.5)	0.002
Systolic pulmonary pressure (mmHg)	48.6±15.6	<0.001	43.1±14.5	0.010	45.5±15.3	<0.001
Coronary artery disease (CAD), n (%)	255 (71.0)	<0.001	346 (54.1)	0.199	952 (51.1)	<0.001
1-CAD	60 (16.7)		99 (15.5)		358 (19.2)	0.083
2-CAD	67 (18.7)	0.087	92 (14.4)	0.381	242 (13.0)	0.020
3-CAD	128 (35.7)	<0.001	155 (24.2)	0.004	352 (18.9)	<0.001
Previous PCI	154 (42.9)	<0.001	188 (29.4)	0.122	488 (26.2)	<0.001
Previous myocardial infarction, n (%)	119 (33.1)	<0.001	114 (17.8)	0.133	285 (15.3)	<0.001
Myocardial infarction <91 days, n (%)	32 (8.9%)	0.123	39 (6.1)	0.552	102 (5.5)	0.050
Previous cardiac surgery, n (%)	110 (30.6)	<0.001	131 (20.5)	0.026	307 (16.5)	<0.001
Diabetes mellitus, n (%)	143 (39.8)	0.588	243 (38.0)	0.009	601 (32.2)	0.002
Mitral regurgitation ≥II°, n (%)	145 (40.4)	<0.001	157 (24.5)	0.032	540 (29.0)	<0.001
Chronic renal failure, n (%) ^a	228 (63.5)	0.343	386 (60.3)	0.003	998 (53.5)	<0.001
Dialysis						
acute	11 (3.1)		11 (1.7)		35 (1.9)	0.288
chronic	16 (4.5)		25 (3.9)		58 (3.1)	0.314
Stroke or TIA, intracranial haemorrhage	36 (10.0)		63 (9.8)		152 (8.2)	0.266
Permanent pacemaker/defibrillator	91 (25.3)	<0.001	96 (15.0)	<0.001	180 (9.7)	<0.001

Values are mean±SD or n (%). ^aChronic renal failure: glomerular filtration rate <60 ml/min/1.73m² or dialysis; [#]*p*-value for pairwise comparison; [†]*p*-value for any intergroup difference; CAD: coronary artery disease; CABG: coronary artery bypass grafting; HGAS: high-gradient aortic stenosis; LEF-LGAS: low ejection fraction, low-gradient aortic stenosis; PLF-LGAS: paradoxical low-flow, low-gradient aortic stenosis




Figure 1. Patient population. AVA: aortic valve area; HGAS: high-gradient severe aortic stenosis; LEF-LGAS: low-EF, low-gradient severe aortic stenosis; PLF-LGAS: “paradoxical” low-flow, low-gradient severe aortic stenosis; TAVI: transcatheter aortic valve implantation

(80.5±5.6 vs. 81.4±6.1; $p<0.001$) and older than patients with LEF-LGAS (80.5±5.6 vs. 79.1±6.1; $p=0.001$). Patients with PLF-LGAS presented with a similar rate of comorbidities compared with patients in the HGAS subgroup. In contrast, the LEF-LGAS subgroup generally had a higher prevalence of comorbidities such as coronary artery disease, pulmonary hypertension, mitral regurgitation, and previous cardiac surgery. This is also reflected by a significantly higher logistic EuroSCORE in the LEF-LGAS group compared to patients with PLF-LGAS and HGAS (36.7±20.1 vs. 22.6±15.7 vs. 24.3±17.4, respectively; $p<0.0001$).

INTERVENTIONAL CHARACTERISTICS

Preoperative haemodynamics and characteristics of the TAVI procedure are presented in **Table 2**. Prior to device implantation the aortic valve area was severely reduced in all subgroups (PLF-LGAS: 0.73±0.17 vs. LEF-LGAS: 0.70±0.17 vs. HGAS: 0.63±0.17 cm²; $p<0.001$). As per definition, the mean transvalvular gradient differed significantly among the three groups: PLF-LGAS 30.7±6.5 mmHg vs. LEF-LGAS 26.5±7.3 mmHg vs. HGAS 55.5±13.8 mmHg ($p<0.001$). There were no differences among the three groups in the access route used. The majority of procedures were performed transfemorally for all subgroups (PLF-LGAS: 68.4% vs. LEF-LGAS: 68.5% vs. HGAS: 71.1%; $p=0.343$). In patients with LEF-LGAS, self-expandable devices were used significantly more often as compared to patients with PLF-LGAS. The majority of interventions were performed as elective procedures. The rate of TAVI procedures classified as “urgent/emergent” was significantly higher in patients with LEF-LGAS (LEF-LGAS 24.0% vs. PLF-LGAS: 14.5% vs. HGAS: 20.9%; $p<0.001$). A procedure was classified as urgent when the patient was haemodynamically stable but medical management was not sufficient for symptom control and timely intervention was required.

RATES OF DEATH AND PREDICTORS OF EARLY MORTALITY AFTER TAVI

While in-hospital mortality was higher in patients with LEF-LGAS compared with HGAS (7.8% vs. 4.9%, $p=0.029$), no significant

difference was observed between patients with HGAS and PLF-LGAS (4.9% vs. 5.3%; $p=0.67$). After one year, the mortality difference was even more pronounced for patients with LEF-LGAS (32.3%) compared with the other two subgroups (PLF-LGAS: 22.3%; $p=0.001$; HGAS: 19.8%; $p<0.001$). In contrast, no significant difference in one-year mortality was observed between the PLF-LGAS and HGAS subgroups ($p=0.192$).

Likewise, the rate of major adverse cardiac and cerebral events (MACCE) at one year (death, MI, and stroke) was significantly higher for patients with LEF-LGAS (LEF-LGAS: 34.5% vs. PLF-LGAS: 27.5; $p=0.021$ vs. HGAS: 23.8%; $p<0.001$) (**Table 3, Figure 2**).

PREDICTORS OF IN-HOSPITAL MORTALITY

Logistic regression analysis of the overall TAVI population for the three groups was performed to assess the predictive value of the subtypes of AS (LEF-LGAS, PLF-LGAS, and HGAS), age >76 years, frailty, diabetes, chronic obstructive pulmonary disease (COPD), three-vessel coronary artery disease (CAD-3), pulmonary hypertension, peripheral vascular disease, previous cardiac operations, myocardial infarction, and LVEF ≤30% for in-hospital mortality. After stepwise analysis, CAD-3, pulmonary hypertension and peripheral vascular disease remained in the model as an independent predictor for in-hospital mortality in the overall TAVI population. No predictive value of the different subtypes of AS for 30-day mortality was observed (LEF-LGAS vs. PLF-LGAS: OR 0.926, $p=0.8$; LEF-LGAS vs. HGAS: OR 0.898, $p=0.69$) in the overall study population.

Multiple logistic regression analysis performed for patients with LEF-LGAS identified pulmonary hypertension (OR 2.337, CI: 1.003-5.444, $p=0.049$), PVD (OR 2.565, CI: 1.140-5.775; $p=0.023$) and previous myocardial infarction (OR 2.539; CI: 1.129-5.707; $p=0.024$) as significant predictors of in-hospital mortality. In patients presenting with PLF-LGAS, the presence of three-vessel CAD (OR 2.38, CI: 1.164-4.868; $p=0.018$) and COPD (OR 2.771, CI: 1.354-5.672, $p=0.005$) were significant predictors of in-hospital mortality. Among patients with HGAS, PVD (OR 1.862, CI: 1.161-2.986;

Table 2. Secondary endpoint: procedural characteristics.

		LEF-LGAS (n=359)	PLF-LGAS (n=640)	HGAS (n=1,864)	p [#]	
Haemodynamics	Ejection fraction	30.3±7.3	60.2±7.8	56.3±12.5	<0.001	
	Aortic valve area, cm ² ±SD	0.70±0.17	0.73±0.17	0.63±0.17	<0.001	
	Mean pressure gradient, mmHg±SD (echo)	26.5±7.3	30.7±6.5	55.5±13.8	<0.001	
	Peak-to-peak gradient, mmHg±SD (invasive)	34.5±14.4	43.0±18.2	63.3±23.4	<0.001	
	Minor calcification*	21 (5.8)	33 (5.2)	64 (3.4)	0.033	
	Moderate calcification*	112 (31.2)	195 (30.5)	403 (21.6)	<0.001	
	Severe calcification*	189 (52.6)	316 (49.4)	1,193 (64.0)	<0.001	
Heart Team approach		173 (48.2)	343 (53.6)	968 (51.9)	0.258	
Duration of procedure, min±SD		98.5±53.2	90.3±54.8	92.2±49.0	0.007	
Access route for valve implantation	Transfemoral, n (%)	246 (68.5)	438 (68.4)	1,325 (71.1)	0.343	
	Apical, n (%)	106 (29.5)	191 (29.8)	500 (26.8)	0.247	
	Transaortic, n (%)	3 (0.8)	5 (0.8)	8 (0.4)	0.385	
	Transaxillary, n (%)	4 (1.1)	6 (0.9)	31 (1.7)	0.429	
Device	Medtronic CoreValve, n (%)	181 (50.4)	253 (39.5)	838 (45.0)	0.003	
	Edwards SAPIEN, n (%)	167 (46.5)	351 (54.8)	910 (48.8)	0.012	
	Other, n (%)	11 (3.1)	36 (5.6)	116 (6.2)	0.051	
General anaesthesia		198 (55.2)	351 (54.8)	1,066 (57.2)	0.514	
Immediate result	Successful device implantation, n (%)	349 (97.2)	623 (97.3)	1,809 (97.0)	0.971	
	Conversion to surgery, n (%)	4 (1.1)	8 (1.3)	31 (1.7)	0.737	
Device function	Peak-to-peak gradient, mmHg±SD		4.1±5.5	5.5±6.7	6.0±9.6	0.140
	Residual aortic regurgitation (AR)	No AR, n (%)	126 (35.1)	274 (42.8)	754 (40.5)	0.056
		AR I°, n (%)	204 (56.8)	328 (51.2)	936 (50.2)	0.072
		AR II°, n (%)	19 (5.3)	28 (4.4)	138 (7.4)	0.016
		AR III°, n (%)	1 (0.3)	0	5 (0.3)	0.453
	AR IV°, n (%)	1 (0.3)	0	1 (0.1)	0.285	
Additional procedures	Adjunctive PCI	6 (1.7)	8 (1.3)	38 (2.0)	0.457	

Values are mean±SD or n (%). *grading according to Rosenhek et al²³. #p-value for any intergroup difference. AR: aortic regurgitation; HGAS: high-gradient aortic stenosis; LEF-LGAS: low ejection fraction, low-gradient aortic stenosis; PCI: percutaneous coronary intervention (%); PLF-LGAS: paradoxical low-flow, low-gradient aortic stenosis

p=0.010) and EF <30% (OR 3.293, CI: 1.436-7.549, p=0.005) were identified as significant predictors of early mortality (Table 4).

Discussion

Low-flow, low-gradient AS with preserved or reduced ejection fraction is a common finding in patients with aortic stenosis. In GARY, PLF-LGAS is observed in 20.8% of patients and is even more frequent than LEF-LGAS (11.7%). Both subgroups together account for one quarter of all patients with AS selected for TAVI.

The three subgroups of AS show clear differences in demographics, gender distribution, and comorbidities. While LEF-LGAS predominantly occurs in male patients, PLF-LGAS and HGAS are slightly more common in female patients (Table 1). Furthermore, patients with LEF-LGAS present with a higher rate of comorbidities such as CAD, COPD, and peripheral vascular disease, whereas the frequency of comorbidities is comparable between patients with PLF-LGAS and HGAS (Table 1). Patients with HGAS have a significantly smaller valve area compared with patients with PLF-LGAS,

a finding that has previously been reported by O'Sullivan et al¹⁹. Although the clinical implications of this finding are not yet clear, we have confirmed it here in a larger patient population.

OUTCOME OF PARADOXICAL LOW-GRADIENT VERSUS HIGH-GRADIENT AS

The impact of low transvalvular flow and gradient in patients with severe aortic stenosis on outcome is a matter of debate and published data so far have shown conflicting results^{14,19}. As a main finding of the present study, patients with PLF-LGAS and HGAS have a comparable overall in-hospital (5.3% vs. 4.9%, p=0.672) and one-year mortality (22.3% vs. 19.8%, p=0.192) after TAVI. The rate of MACCE was not significantly different between these two subgroups at hospital discharge (8.9% vs. 7.9%, p=0.4) and at one year (27.5% vs. 23.08%; p=0.063) after TAVI. These results are in line with data from the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial, which reported comparable outcomes in patients with low flow and preserved ejection fraction versus normal flow²⁴. As in

Table 3. Primary endpoints: mortality and MACCE – in-hospital and at 12-month follow-up.

	LEF-LGAS (n=359)	$p^{\#}$ LEF-LGAS vs. PLF-LGAS	PLF-LGAS (n=640)	$p^{\#}$ HGAS vs. PLF-LGAS	HGAS (n=1,864)	$p^{\#}$ LEF-LGAS vs. HGAS	p^{\dagger}
In-hospital mortality	28 (7.8)	0.133	34 (5.3)	0.674	91 (4.9)	0.029	0.084
Combined endpoints (in-hospital)							
MACCE (death, MI, stroke)	40 (11.1%)	0.266	57 (8.9%)	0.404	147 (7.9%)	0.048	0.121
Combined MAE (MACCE, re-op, bleeding (≥ 1 unit), new dialysis)	140 (39.0%)	1.000	250 (39.1%)	0.351	768 (41.2%)	0.447	0.538
12-month mortality	116 (32.3)	0.001	143 (22.3)	0.192	370 (19.8)	<0.001	<0.001
Patient alive	235 (65.5)	0.001	483 (75.5)	0.229	1,451 (77.8)	<0.001	<0.001
Survival status unknown	8 (2.2)	1.000	14 (2.2)	1.000	43 (2.2)	1.000	1.000
Cause of death	Cardiovascular	43 (12.0)	50 (7.8)	0.057	105 (5.6)	<0.001	<0.001
	Non-cardiovascular	22 (6.1)	26 (4.1)	0.821	81 (4.3)	0.169	0.273
	Unknown	51 (14.2)	67 (10.5)	0.648	184 (9.9)	0.019	0.050
Combined endpoints (12-month)							
No MACCE	193 (53.8)	0.038	388 (60.6)	0.096	1,199 (64.3)	<0.001	0.001
MACCE (death, MI, stroke)	124 (34.5)	0.021	176 (27.5)	0.063	443 (23.8)	<0.001	<0.001
Patient alive but MACCE unknown	42 (11.7)	1.000	76 (11.9)	1.000	222 (11.9)	1.000	0.994

Values are mean \pm SD or n (%). \dagger p-value for any intergroup difference. $\#$ p-value for pairwise comparison. HGAS: high-gradient aortic stenosis; LEF-LGAS: low ejection fraction, low-gradient aortic stenosis; MACCE: major adverse cardiac and cerebral events; MAE: major adverse events; PLF-LGAS: paradoxical low-flow, low-gradient aortic stenosis

the GARY registry, treatment decisions in the SEAS trial were not randomised but based on clinical practice.

However, our observations also contradict some of the findings of earlier studies. In a retrospective analysis of the Placement of Aortic Transcatheter Valves (PARTNER) trial, Herrmann et al observed a significantly higher one-year mortality in patients with

a low transvalvular flow (47% versus 34%; hazard ratio 1.5; 95% CI: 1.25-1.89; $p=0.006$), which is generally defined as a stroke volume index ≤ 35 ml/m²¹⁸. In clinical practice, the flow decrease may be caused by a high valvuloarterial impedance and a restrictive filling pattern (as in PLF-LGAS) or by impaired LV contractility (as in LEF-LGAS). In the study by Herrmann et al, a “low-flow” condition




Figure 2. Survival at 30 days and one year after TAVI in low-flow, low-gradient aortic stenosis with preserved and reduced ejection fraction vs. high-gradient aortic stenosis. Kaplan-Meier survival curves for patients with severe AS after TAVI stratified by transvalvular gradient. A) 30-day-mortality and B) one-year mortality curves and numbers at risk after transcatheter aortic valve replacement stratified for patients with low EF-low-gradient (marked red), paradoxical low-gradient (marked blue) and high-gradient aortic stenosis (marked green). In patients with low-gradient aortic stenosis, 30-day mortality is moderately, albeit significantly, higher compared with patients with high-gradient aortic stenosis (log-rank test: $p=0.0194$).

Table 4. Predictors of in-hospital mortality for patients with LEF-LG, PLF-LG, and HG aortic stenosis.

	LEF-LGAS				PLF-LGAS				HGAS			
	p*-value	Odds ratio	95% CI for odds ratio		p*-value	Odds ratio	95% CI for odds ratio		p*-value	Odds ratio	95% CI for odds ratio	
			Lower	Upper			Lower	Upper			Lower	Upper
EF <30	0.734				–	–	–	–	0.005	3.293	1.436	7.549
PVD	0.023	2.565	1.140	5.775	0.213	–	–	–	0.010	1.862	1.161	2.986
Age >76	0.683	–	–	–	0.544	–	–	–	0.379	–	–	–
Frailty	0.644	–	–	–	0.741	–	–	–	0.453	–	–	–
PH	0.049	2.337	1.003	5.444	0.893	–	–	–	0.212	–	–	–
Previous surgery	0.490	–	–	–	0.764	–	–	–	0.583	–	–	–
Diabetes mellitus	0.511	–	–	–	0.882	–	–	–	0.156	–	–	–
Previous MI	0.024	2.539	1.129	5.707	0.877	–	–	–	0.350	–	–	–
COPD	0.416	–	–	–	0.005	2.771	1.354	5.672	0.235	–	–	–
3-CAD	0.200	–	–	–	0.018	2.380	1.164	4.868	0.538	–	–	–

Results of logistic regression analysis performed in subgroups with either low ejection fraction low-gradient, paradoxical low-gradient, or high-gradient aortic stenosis. This table includes the variables that were significant ($p < 0.05$) in univariate analyses. CAD: coronary artery disease; CI: confidence interval; COPD: chronic obstructive pulmonary disease; HGAS: high-gradient aortic stenosis; LEF-LGAS: low ejection fraction, low-gradient aortic stenosis; MI: myocardial infarction; OR: odds ratio; PH: pulmonary hypertension; PLF-LGAS: paradoxical low-flow, low-gradient aortic stenosis; PVD: peripheral vessel disease; *p-value for multivariate testing.

was identified as a powerful predictor of early mortality, thus suggesting that a low forward LV output is a more important determinant of outcome than the mechanism of flow decrease¹⁸. Thus, in the study by Herrmann et al, the higher mortality among patients with low-flow AS is potentially due to the inclusion of patients with impaired systolic LV function, a subgroup which in clinical practice presents with a higher rate of comorbidities. Another recent study by Le Ven et al confirmed a higher mortality in patients with aortic stenosis and low-flow transvalvular flow without observing an impact of LV systolic dysfunction on mortality in multivariate analysis²⁵. This finding may have been influenced by the smaller number of patients with reduced LV function as well as the comparatively long period of retrospective patient inclusion and the retrospective nature of the study.

Our finding of a comparable outcome between PLF-LGAS and HGAS on the one hand and a significantly higher mortality of LEF-LGAS on the other suggests that the main cause of the increased mortality after TAVI is not decreased flow itself, but rather the reduced ejection fraction as a mechanism for reduced flow and the associated comorbidities of the LEF-LGAS subgroup. This is further supported by the results of the multiple regression analysis, which identified an EF <30% as a predictor of in-hospital mortality among patients with HGAS. Although flow data are not available in the GARY population and PLF-LGAS was defined based on AVA/BSA and MPG, a paradoxical low transvalvular gradient in the setting of severe AS is inevitably the result of a low transvalvular flow.

The subgroup differences in mortality between GARY and PARTNER may be further explained by the study design. While the PARTNER trial was conducted in a highly selected study population and included only balloon-expandable valves, the present analysis reflects the results of TAVI in an unselected, all-comers patient population with paradoxical low-gradient AS and includes all commercially available TAVI devices.

OUTCOME OF LOW-FLOW, LOW-GRADIENT AS

Left ventricular dysfunction is associated with adverse outcomes after surgical aortic valve replacement, but little is known about the impact of LV dysfunction on outcomes after TAVI^{13,14,26-28}. This is confirmed by the GARY data where one-year mortality of LEF-LGAS is significantly higher compared with that of the other AS subtypes (LEF-LGAS: 32.3% vs. PLF-LGAS: 22.3% vs. HGAS: 19.8%; $p = 0.001$). This difference is in part attributable to a higher rate of cardiovascular deaths among patients with low flow and LV dysfunction (LEF-LGAS: 12% vs. PLF-LGAS 7.8% vs. HGAS 5.6%; $p < 0.001$). Furthermore, patients with LEF-LGAS had a higher rate of low cardiac output syndrome and more frequently required cardiopulmonary resuscitation or mechanical circulatory support during the post-interventional period than their counterparts in the other subgroups (Table 5).

The current results confirm a substantial improvement in the early outcome after TAVI among patients with LEF-LGAS compared with earlier, non-randomised data from the German TAVI registry for the period 2009-2010. In this registry, in-hospital and one-year mortalities of 16.1% and 36.9%, respectively, were reported in this subgroup^{14,29}. The current data show a more than 50% decrease in in-hospital mortality (to 7.8%) despite a higher EuroSCORE in the GARY subgroup (GARY: 36.7 ± 20.9 vs. German TAVI registry: 26.8 ± 9.7)¹⁴. This improvement in outcome can most likely be attributed to factors such as the increase in operator experience, the downsizing of TAVI devices, and a learning curve in patient selection. However, one-year mortality in the LEF-LGAS subgroup improved only slightly, from 36.9% in the German TAVI registry to 32.3% in the GARY registry. This observation reflects the severity of the underlying cardiac disease in this difficult subgroup which can be only partially reversed by aortic valve replacement and ultimately results in an increased long-term mortality.

Table 5. Secondary endpoints in-hospital: early complications classified according to VARC¹³.

	LEF-LGAS (n=359)	<i>p</i> [#] LEF-LGAS vs. PLF-LGAS	PLF-LGAS (n=640)	<i>p</i> [#] HGAS vs. PLF-LGAS	HGAS (n=1,864)	<i>p</i> [#] LEF-LGAS vs. HGAS	<i>p</i> [#]
Duration of treatment on ICU	4.3±5.3		4.0±6.3		3.8±5.2		0.321
Postoperative complications							
Low cardiac output	35 (9.7)	0.003	31 (4.8)	0.107	125 (6.7)	0.045	0.013
Medical treatment	18 (5.0)	0.013	13 (2.0)	0.320	54 (2.9)	0.049	0.034
Intra-aortic balloon pump	5 (1.4)	0.006	0 (0.0)	0.027	14 (0.8)	0.215	0.009
Other type of circulatory support	12 (3.3)	–	18 (2.8)	–	57 (3.1)	–	0.883
Myocardial infarction	3 (0.8)	–	1 (0.2)	–	8 (0.4)	–	0.240
Stroke	12 (3.3)	–	24 (3.8)	–	63 (3.4)	–	0.895
Minor stroke (Rankin score <2)	7 (1.9)	–	13 (2.0)	–	28 (1.5)	–	0.536
Major stroke (Rankin score ≥2)	5 (1.4)	–	11 (1.7)	–	35 (1.9)	–	0.891
Acute kidney injury (modif. RIFLE classification)							
Stage 1 (creatinine increase 150-199%)	19/130 (14.6)	–	43/252 (17.1)	–	129/862 (15.0)	–	0.697
Stage 2 (creatinine increase 200-299%)	7/130 (5.4)	–	12/252 4.8	–	42/862 4.9	–	0.962
Stage 3 (creatinine increase >300%)	8/130 (6.2)	–	7/252 (2.8)	–	21/862 (2.4)	–	0.062
Vascular complications	47 (13.1)	–	75 (11.7)	–	236 (12.7)	–	0.769
Bleeding complications							
Life-threatening or disabling (≥4 RBC units)	44 (12.3)	–	70 (10.9)	–	208 (11.2)	–	0.791
Major bleeding (2 or 3 RBC units)	59 (16.4)	–	112 (17.5)	–	368 (19.7)	–	0.217
Minor bleeding (1 RBC unit)	12 (3.3)	–	31 (4.8)	–	100 (5.4)	–	0.277
Number unknown but ≥1	8 (2.2)	–	8 (1.3)	–	22 (1.2)	–	0.272
Cardiopulmonary resuscitation	28 (7.8)	0.006	23 (3.6)	0.225	90 (4.8)	0.028	0.016
Permanent pacemaker/defibrillator (new)	64 (23.9)	–	109 (20.0)	–	377 (22.4)	–	0.383
Postoperative day of mobilisation							
Day 1	155 (43.2)	–	286 (44.7)	–	870 (46.7)	–	0.392
Day 2	98 (27.3)	–	148 (23.1)	–	445 (23.9)	–	0.303
≥Day 3	60 (16.7)	–	128 (20.0)	–	358 (19.2)	–	0.434
Values are mean±SD or n (%). # <i>p</i> -value for pairwise comparison; * <i>p</i> -value for any intergroup difference; HGAS: high-gradient aortic stenosis; IABP: intra-aortic counterpulsation; LEF-LGAS: low ejection fraction, low-gradient aortic stenosis; PLF-LGAS: paradoxical low-flow, low-gradient aortic stenosis; RBC: packed red blood cells							

Limitations

The present paper reports the largest non-randomised series of patients undergoing TAVI for the different subtypes of AS reported to date. However, as it is based on registry data, several limitations apply. Firstly, only data on AVA, MPG, and EF but not transaortic flow are available for further classification of AS. In patients with both an indexed valve area of ≤0.6 cm²/m² and an MPG of <40 mmHg, the presence of a reduced transvalvular flow was assumed, and they were therefore allocated to the PLF-LGAS and the LEF-LGAS subgroups. Secondly, particularly for patients with LEF-LGAS, dobutamine stress echocardiography (DES) would be required to exclude patients with pseudostenosis from valve replacement. Since the GARY registry is a nationwide registry of data from cardiology and surgical units, it focuses on a limited range of variables excluding the results of DES. In patients with impaired LV function, further studies should also include data on postoperative recovery of LV function, which may also serve as an indicator for better outcome. Additionally, the EuroSCORE I was

used for calculation of perioperative risk, which has been demonstrated to overestimate the 30-day risk of mortality.

Conclusions

In contrast to other studies, the present report summarises a large number of patients and their clinical follow-up from a nationwide registry (nearly all TAVI-performing institutions in Germany). As the time period for inclusion was short, a learning curve and technological changes do not impact on the results. In clinical practice, a low transvalvular flow and gradient despite severe AS is a common finding and is observed in >30% of patients undergoing TAVI. In the GARY registry, paradoxical low-gradient AS is observed in 20.8% of patients and is even more frequent than low-gradient AS with impaired LV function (11.7%). The in-hospital and one-year mortality and complication rates after TAVI among patients with PLF-LGAS are low and similar to the rates for high-gradient AS. In contrast, patients with LEF-LGAS have a significantly higher one-year mortality and a significantly higher rate of low cardiac output after TAVI.

Impact on daily practice

The present study analyses the outcome of patients undergoing transcatheter aortic valve implantation (TAVI) for different subtypes of severe aortic stenosis (AS) based on data from the GARY registry. In this study population a low transvalvular flow and gradient is a common finding and is observed in >30% of patients. A “paradoxical” low-gradient AS despite preserved left ventricular (LV) function is present in 20.8% of TAVI patients and is even more frequent than a low-gradient AS with impaired LV function (11.7%). Early and one-year mortality and complication rates after TAVI for paradoxical low-gradient AS are low and comparable to the rates for high-gradient AS. In contrast, TAVI for low-gradient AS and reduced LV function is associated with significantly higher one-year mortality and rate of MACCE.

Conflict of interest statement

A. Lauten has received proctor salary and/or consulting fees from St. Jude Medical, JenaValve and Occlutech. C. Hamm has received speakers' honoraria from Medtronic and Edwards Lifesciences and serves on the advisory board of Medtronic. H. Möllmann has received proctor salary and/or speakers' honoraria from Abbott, Medtronic, Edwards Lifesciences, St. Jude Medical, and Symetis. H. Figulla is a co-founder of JenaValve and received consulting fees from that company. R. Zahn has received research grants from Medtronic and Edwards Lifesciences. K. Kuck is a consultant for Biosense Webster, St. Jude Medical, Stereotaxis, and Medtronic. M. Böhm has received speakers' honoraria and scientific support from Medtronic, St. Jude Medical, Boston Scientific, Servier, Boehringer Ingelheim and Menarini. The other authors have no conflicts of interest to declare.

References

1. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, Gaasch WH, Lytle BW, Nishimura RA, O'Gara PT, O'Rourke RA, Otto CM, Shah PM, Shanewise JS; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol.* 2008;52:e1-142.
2. Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC); European Association for Cardio-Thoracic Surgery (EACTS), Vahanian A, Alfieri O, Andreotti F, Antunes MJ, Baron-Esquivias G, Baumgartner H, Borger MA, Carrel TP, De Bonis M, Evangelista A, Falk V, Jung B, Lancellotti P, Pierard L, Price S, Schafers HJ, Schuler G, Stepinska J, Swedberg K, Takkenberg J, Von Oppell UO,

Windecker S, Zamorano JL, Zembala M. Guidelines on the management of valvular heart disease (version 2012). *Eur Heart J.* 2012;33:2451-96.

3. Miller DC, Blackstone EH, Mack MJ, Svensson LG, Kodali SK, Kapadia S, Rajeswaran J, Anderson WN, Moses JW, Tuzcu EM, Webb JG, Leon MB, Smith CR; PARTNER Trial Investigators and Patients; PARTNER Stroke Substudy Writing Group and Executive Committee. Transcatheter (TAVR) versus surgical (AVR) aortic valve replacement: occurrence, hazard, risk factors, and consequences of neurologic events in the PARTNER trial. *J Thorac Cardiovasc Surg.* 2012;143:832-843.e13.

4. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S; PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med.* 2010;363:1597-607.

5. Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, Derumeaux G, Anselme F, Laborde F, Leon MB. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. *Circulation.* 2002;106:3006-8.

6. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Williams M, Dewey T, Kapadia S, Babaliaros V, Thourani VH, Corso P, Pichard AD, Bavaria JE, Herrmann HC, Akin JJ, Anderson WN, Wang D, Pocock SJ; PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *N Engl J Med.* 2011;364:2187-98.

7. Lauten J, Rost C, Breithardt OA, Seligmann C, Klinghammer L, Daniel WG, Flachskampf FA. Invasive hemodynamic characteristics of low gradient severe aortic stenosis despite preserved ejection fraction. *J Am Coll Cardiol.* 2013;61:1799-808.

8. Pibarot P, Dumesnil JG. Low-flow, low-gradient aortic stenosis with normal and depressed left ventricular ejection fraction. *J Am Coll Cardiol.* 2012;60:1845-53.

9. Dumesnil JG, Pibarot P. Low-flow, low-gradient severe aortic stenosis in patients with normal ejection fraction. *Curr Opin Cardiol.* 2013;28:524-30.

10. Clavel MA, Dumesnil JG, Capoulade R, Mathieu P, Senechal M, Pibarot P. Outcome of patients with aortic stenosis, small valve area, and low-flow, low-gradient despite preserved left ventricular ejection fraction. *J Am Coll Cardiol.* 2012;60:1259-67.

11. Hachicha Z, Dumesnil JG, Bogaty P, Pibarot P. Paradoxical low-flow, low-gradient severe aortic stenosis despite preserved ejection fraction is associated with higher afterload and reduced survival. *Circulation.* 2007;115:2856-64.

12. Monin JL, Quere JP, Monchi M, Petit H, Baleynaud S, Chauvel C, Pop C, Ohlmann P, Lelguen C, Dehant P, Tribouilloy C, Gueret P. Low-gradient aortic stenosis: operative risk stratification and predictors for long-term outcome: a multicenter study using dobutamine stress hemodynamics. *Circulation.* 2003;108:319-24.

13. Levy F, Laurent M, Monin JL, Maillet JM, Pasquet A, Le Tourneau T, Petit-Eisenmann H, Gori M, Jobic Y, Bauer F, Chauvel C, Leguerrier A, Tribouilloy C. Aortic valve replacement for low-flow/low-gradient aortic stenosis operative risk stratification and long-term outcome: a European multicenter study. *J Am Coll Cardiol*. 2008;51:1466-72.
14. Lauten A, Zahn R, Horack M, Sievert H, Linke A, Ferrari M, Harnath A, Grube E, Gerckens U, Kuck KH, Sack S, Senges J, Figulla HR; German Transcatheter Aortic Valve Interventions Registry Investigators. Transcatheter aortic valve implantation in patients with low-flow, low-gradient aortic stenosis. *JACC Cardiovasc Interv*. 2012;5:552-9.
15. Dumesnil JG, Pibarot P, Carabello B. Paradoxical low flow and/or low gradient severe aortic stenosis despite preserved left ventricular ejection fraction: implications for diagnosis and treatment. *Eur Heart J*. 2010;31:281-9.
16. Minners J, Allgeier M, Gohlke-Baerwolf C, Kienzle RP, Neumann FJ, Jander N. Inconsistent grading of aortic valve stenosis by current guidelines: haemodynamic studies in patients with apparently normal left ventricular function. *Heart*. 2010;96:1463-8.
17. Barasch E, Fan D, Chukwu EO, Han J, Passick M, Petillo F, Norales A, Reichek N. Severe isolated aortic stenosis with normal left ventricular systolic function and low transvalvular gradients: pathophysiologic and prognostic insights. *J Heart Valve Dis*. 2008;17:81-8.
18. Herrmann HC, Pibarot P, Hueter I, Gertz ZM, Stewart WJ, Kapadia S, Tuzcu EM, Babaliaros V, Thourani V, Szeto WY, Bavaria JE, Kodali S, Hahn RT, Williams M, Miller DC, Douglas PS, Leon MB. Predictors of mortality and outcomes of therapy in low-flow severe aortic stenosis: a Placement of Aortic Transcatheter Valves (PARTNER) trial analysis. *Circulation*. 2013;127:2316-26.
19. O'Sullivan CJ, Stortecky S, Heg D, Pilgrim T, Hosek N, Buellesfeld L, Khattab AA, Nietlispach F, Moschovitis A, Zanchin T, Meier B, Windecker S, Wenaweser P. Clinical outcomes of patients with low-flow, low-gradient, severe aortic stenosis and either preserved or reduced ejection fraction undergoing transcatheter aortic valve implantation. *Eur Heart J*. 2013;34:3437-50.
20. Hamm CW, Mollmann H, Holzhey D, Beckmann A, Veit C, Figulla HR, Cremer J, Kuck KH, Lange R, Zahn R, Sack S, Schuler G, Walther T, Beyersdorf F, Bohm M, Heusch G, Funkat AK, Meinertz T, Neumann T, Papoutsis K, Schneider S, Welz A, Mohr FW; GARY-Executive Board. The German Aortic Valve Registry (GARY): in-hospital outcome. *Eur Heart J*. 2014;35:1588-98.
21. Beckmann A, Hamm C, Figulla HR, Cremer J, Kuck KH, Lange R, Zahn R, Sack S, Schuler GC, Walther T, Beyersdorf F, Bohm M, Heusch G, Funkat AK, Meinertz T, Neumann T, Papoutsis K, Schneider S, Welz A, Mohr FW; GARY Executive Board. The German Aortic Valve Registry (GARY): a nationwide registry for patients undergoing invasive therapy for severe aortic valve stenosis. *Thorac Cardiovasc Surg*. 2012;60:319-25.
22. Kappetein AP, Head SJ, Génèreux P, Piazza N, van Mieghem NM, Blackstone EH, Brott TG, Cohen DJ, Cutlip DE, van Es GA, Hahn RT, Kirtane AJ, Krucoff MW, Kodali S, Mack MJ, Mehran R, Rodès-Cabau J, Vranckx P, Webb JG, Windecker S, Serruys PW, Leon MB. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. *Eur Heart J*. 2012;33:2403-18.
23. Kottling J, Schiller W, Beckmann A, Schafer E, Dobler K, Hamm C, Veit C, Welz A. German Aortic Valve Score: a new scoring system for prediction of mortality related to aortic valve procedures in adults. *Eur J Cardiothorac Surg*. 2013;43:971-7.
24. Jander N, Minners J, Holme I, Gerds E, Boman K, Brudi P, Chambers JB, Egstrup K, Kesaniemi YA, Malbecq W, Nienaber CA, Ray S, Rossebo A, Pedersen TR, Skjaerpe T, Willenheimer R, Wachtell K, Neumann FJ, Gohlke-Barwolf C. Outcome of patients with low-gradient "severe" aortic stenosis and preserved ejection fraction. *Circulation*. 2011;123:887-95.
25. Le Ven F, Freeman M, Webb J, Clavel MA, Wheeler M, Dumont E, Thompson C, De Laroche R, Moss R, Doyle D, Ribeiro HB, Urena M, Nombela-Franco L, Rodès-Cabau J, Pibarot P. Impact of low flow on the outcome of high-risk patients undergoing transcatheter aortic valve replacement. *J Am Coll Cardiol*. 2013;62:782-8.
26. Connolly HM, Oh JK, Orszulak TA, Osborn SL, Roger VL, Hodge DO, Bailey KR, Seward JB, Tajik AJ. Aortic valve replacement for aortic stenosis with severe left ventricular dysfunction. Prognostic indicators. *Circulation*. 1997;95:2395-400.
27. Connolly HM, Oh JK, Schaff HV, Roger VL, Osborn SL, Hodge DO, Tajik AJ. Severe aortic stenosis with low transvalvular gradient and severe left ventricular dysfunction: result of aortic valve replacement in 52 patients. *Circulation*. 2000;101:1940-6.
28. Tribouilloy C, Levy F, Rusinaru D, Gueret P, Petit-Eisenmann H, Baleynaud S, Jobic Y, Adams C, Lelong B, Pasquet A, Chauvel C, Metz D, Quere JP, Monin JL. Outcome after aortic valve replacement for low-flow/low-gradient aortic stenosis without contractile reserve on dobutamine stress echocardiography. *J Am Coll Cardiol*. 2009;53:1865-73.
29. Zahn R, Gerckens U, Grube E, Linke A, Sievert H, Eggebrecht H, Hambrecht R, Sack S, Hauptmann KE, Richardt G, Figulla HR, Senges J; German Transcatheter Aortic Valve Interventions-Registry Investigators. Transcatheter aortic valve implantation: first results from a multi-centre real-world registry. *Eur Heart J*. 2011;32:198-204.